Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Pharmacokinetics
Interventions: DRUG: SPI-2012
Sponsor: Spectrum Pharmaceuticals, Inc